Description: SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
Home Page: www.skbioscience.co.kr
310, Pangyo-ro
Seongnam-si,
13494
South Korea
Phone:
82 2 2008 2200
Officers
| Name | Title |
|---|---|
| Mr. Jae-Yong Ahn | CEO, Pres & Director |
| Mr. Hoon Kim | CTO & Exec. Director |
| Ms. SookMi Hwang | Head of Global Regulatory Affairs |
| Dr. Jin-yong Park | Head of Quality Unit |
| Dr. Harry Kleanthous | Exec. VP of Vaccine R&D Strategy & External Innovation |
| Dr. Sally Choe | Head of Global Clinical Devel. & Regulatory Affairs |
Exchange: KO
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 31.746 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.0087 |
| Price-to-Sales TTM: | 8.3861 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |